BEVERLY, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Corporation announced today that it has closed a Series C financing, raising $19.3 million. All of Inotek’s previous investors participated in the round, including Care Capital LLC, La Caisse de dépôt et placement du Québec, MedImmune Ventures, Pitango Venture Capital, and Rho Ventures. Inotek added three additional investors in the Series C round: Hercules Technology Growth Capital, Inc., Meditor Capital Management, and Mitsubishi UFJ Capital.
